In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Features of the vascular remodeling in men with prehypertension

Session Poster Session III - Friday 08:30 - 12:30

Speaker Irina Osipova

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session

Authors : V Kondakov (Barnaul,RU), O Antropova (Barnaul,RU), I Osipova (Barnaul,RU), E Besklubova (Barnaul,RU)

Authors:
V Kondakov1 , O Antropova1 , I Osipova1 , E Besklubova2 , 1Altay State Medical University - Barnaul - Russian Federation , 2Railway Clinical Hospital - Barnaul - Russian Federation ,

Citation:

Aim: to explore the features of vascular remodeling in patients with prehypertension compared with hypertension.
All patients were divided into groups: the 1-st - 30 men with prehypertension (PHTN), second - 30 men with diagnosed hypertension (HTN), control group-30 healthy volunteers. The age was 46.1±8.3, 47.7±8.5 and 48.1±7.4 years. The CV risk factors, atherosclerosis markers, endothelium dependent vasodilatation (EDVD) were evaluated. The arterial stiffness and central systolic blood pressure (CBP) were performed on the SphygmoCor (AtCor Medical Pty Limited.).
Results. PHTN patients were at a comparable rate of modifiable risk factor, has a lower incidence of abdominal obesity (16%), compared to the HT patients - (40%) (p <0.05). ABI <0.9 was found in 30% and 38% of patients in the 1st and 2nd group, 18% in the control group (p <0,005). IMT was 0,7 ± 0,02 and 0,8 ± 0,08 mm in both groups. Carotid atherosclerosis were diagnosed in 30% of the PHTN and 55% of HTN (p <0,005), 17% in the control (p <0,005). Endothelial dysfunction was found in 57.6% In the 1st group and in 42.4% in 2nd (?2 = 5,6, p <0.05). The combination of endothelial dysfunction and atherosclerosis was in the 54.3% for the 1st group and 82,1% - 2nd , (p <0,05). Arterial stiffness index (SI) was 5,5 ± 1,85 m/s in the control group, 7,20±1,99 m/s in the 1st group, 8,90±1 85 m/s in the 2nd, which is higher than in the control group (p <0,005). The reflection index (RI) was higher in the both test groups compared to control (35,46 ± 14,50%, 36,59 ± 15,43% and 30,39 ± 13,43% respectively, p <0,005). AI in the groups was comparable with healthy volunteers. PWV> 10 m/s was found in 3% and 5% in the 1st and 2nd groups, respectively. According to the age, among the 31-50 years old patients, 80% in the 1st group and 70% in the 2nd had a higher then a normal PWV (6.6 m/s). At the age of 50, 66% in the 1st group and 50% in the 2nd group had the result higher than 8.5 m/s. AIx and AIx75 in HT patients were higher than in the control group by 10% (p <0,005), Spa at 20 mm Hg (p <0,005). 
Conclusions. PHTN men under the age of 55 years have a lower incidence of carotid atherosclerosis and comparable signs of lower limbs atherosclerosis, comparable incidence of arteriosclerosis. However, these figures differ from healthy patients. Already at the age of 31-50 years, the majority of patients (80%) have indicators of vascular stiffness, not corresponding to the normal values. In these patients there is a tendency to increasing CBP. Endothelial dysfunction in PHTN is more common than in patients with hypertension, but it is less combined atherosclerosis.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are